Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.72 |
| ▸ | RXRA | P19793 | 1/20 | 0.69 |
| ▸ | RXRB | P28702 | 1/20 | 0.69 |
| ▸ | RXRG | P48443 | 1/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL9626623 | 0.95 | RXRA (0.68) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL21407 | 0.93 | RXRA (0.66) | MAOBRXRARXRBRXRGNR4A2 | |
| Alcohol SCHEMBL9628500 | 0.92 | RXRA (0.64) | MAOBRXRARXRBRXRGNR4A2 | |
| Ethylamine SCHEMBL9628064 | 0.90 | MAOB (0.69) | MAOBRXRARXRBRXRGNR4A2 | |
| Isopropylamine SCHEMBL9628060 | 0.90 | MAOB (0.65) | MAOBRXRARXRBRXRGNR4A2 | |
| Propanol SCHEMBL9627268 | 0.89 | RXRA (0.61) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL3823697 | 0.89 | RXRA (0.69) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL1548932 | 0.86 | F10 (0.62) | MAOBNR4A2MAOAALOX5CYP1A2 | |
| SCHEMBL3624161 | 0.85 | MAOB (0.73) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL28854357 | 0.84 | MAOB (0.67) | MAOBRXRARXRBRXRGMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104059055-B | 1,2, 3-triazole compound and preparation method and application thereof | 常州大学 | 2016-08-31 | — | — | CN | disclosed |
| CN-105440020-A | 1,2,3-triazole compounds with antitumor activity and preparation method for 1,2,3-triazole compounds | UNIV CHANGZHOU | 2016-03-30 | — | — | CN | disclosed |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. | 2012-10-18 | — | — | US | disclosed |
| EP-1994004-B1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | MAOB 3/4885RXRA 2729/4885RXRB 3008/4885 |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | CBR1, CNR1, CBR3 | MAOB 569/4885RXRA 1761/4885RXRB 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.